[Pain therapy in patients with tumors. According to graduated schedule and hourly plan].
出版信息
MMW Fortschr Med. 2003 Oct 2;145(40):53.
PMID:14603608
Abstract
摘要
相似文献
1
[Pain therapy in patients with tumors. According to graduated schedule and hourly plan].
MMW Fortschr Med. 2003 Oct 2;145(40):53.
2
[Pain therapy with semisynthetic opioids. Patients have opioid-type side effects more rarely].
MMW Fortschr Med. 2003 Jul 10;145(27-28):50.
3
Hydromorphone-OROS formulation.
Expert Opin Pharmacother. 2010 May;11(7):1207-14. doi: 10.1517/14656566.2010.482099.
4
[Delayed action and rapidly effective in combination. Hydromorphone--already a WHO stage 3 drug].
MMW Fortschr Med. 2006 May 11;148(19):47.
5
Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Clin Ther. 2006 Jan;28(1):86-98. doi: 10.1016/j.clinthera.2006.01.010.
6
Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Am J Geriatr Pharmacother. 2009 Feb;7(1):1-10. doi: 10.1016/j.amjopharm.2009.02.002.
7
Transitioning a cancer patient from high-dose intravenous hydromorphone therapy to intravenous methadone.
J Pain Palliat Care Pharmacother. 2011;25(4):356-61. doi: 10.3109/15360288.2011.620688.
8
[Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
MMW Fortschr Med. 2004 Dec 9;146(Suppl 3-4):95-8.
9
Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Curr Med Res Opin. 2007 Oct;23(10):2333-45. doi: 10.1185/030079907X219643.
10
[Pain therapy. Extensive possibilities not adequately utilized].
MMW Fortschr Med. 2005 May 12;147(19):60-1.
Zotero 插件